Luspatercept

Drug Profile

Luspatercept

Alternative Names: ACE-536

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Acceleron Pharma
  • Developer Acceleron Pharma; Celgene Corporation
  • Class Antianaemics; Disulfides; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
  • Mechanism of Action TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia; Myelodysplastic syndromes
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Beta-thalassaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Beta-thalassaemia; Myelodysplastic syndromes
  • Phase II Anaemia
  • Preclinical Sickle cell anaemia

Most Recent Events

  • 09 Jan 2017 Acceleron Pharma plans a phase II trial for beta-thalassaemia
  • 09 Jan 2017 Acceleron Pharma plans a phase II trial for Myelodysplastic Syndromes
  • 04 Dec 2016 Updated efficacy and adverse events data from two phase II trials in Myelodysplastic Syndromes presented at the at the 58th Annual Meeting of the American Society of Hematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top